Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 FY2018 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Sep 28, 2017
Slide 1: First Quarter 2018 Earnings Presentation
AngioDynamics First Quarter 2018 Earnings Presentation September 28, 2017 angiodynamics
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward LookingStatements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash fl
Slide 3: Q1 FY2018 Highlights
Q1 FY2018 Highlights * Revenue of $85.4 million, down 3% year-over-year (Excluding impact of Cook Recall: Revenue down 1% year-over-year) * Adj. EPS of $0.12, compared to $0.17 year-over-year + Adj. EBITDAS of $10.6 million, compared to $14.2 million year-over-year * Generated operating cash flow of
Slide 4: First Quarter 2018 Results
First Quarter 2018 Results FY2018 FY2017 S in millions (except per share) Q1 Results Q1 Results Change Revenue $85.4 $88.1 (3)% - Peripheral Vascular 49.9 52.0 (4)% - Vascular Access 23.2 25.0 (7)% _Oncology/Surgery 30 1% - United States 68.9 72.2 (5)% - International 16.5 159 A% Net Income ($0.0) $
Slide 5: Reiterating FY2018 Guidance
Reiterating FY2018 Guidance FY2017 Actuals FY2018 Guidance Revenue $349.6m $352-$359m Adjusted EPS S0 re $0.64-50.68 | F recahFow = 65) 7m 35mm FOCUS | EXECUTION | ACCOUNTABILITY ® angiodynamics
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation ® angiodynamics
Slide 7: Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income and EPS
Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income and EPS Reconciliation of Gross Profit to non-GAAP Adjusted Gross Profit: Three months ended August 3, “August, 2017 2016 (naueited) Gross profit $ 41.229 $45,032 Inventory charge included in cost of sales _ Adjusted gross profit EEE aa Adj
Slide 8: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS Three months ended August 31, August 31, 2017 2016 (unaudited) Net income (loss) $ (35) $ 1,300 Income tax expense 19 1,603 Interest expense 759, 723 Depreciation and amortization 5,716 6,042 Stock-based compensation 1,797 1,684 EBITDAS $ 8
Slide 9: Growth through Focus, Execution, Accountability
Growth through Focus Execution Accountablity angiodynamics